Drug General Information
Drug ID
D0B5RZ
Former ID
DIB009400
Drug Name
GS-6620
Synonyms
GS-441326; NS5B polymerase inhibitor (HCV infection), Gilead Sciences
Drug Type
Small molecular drug
Indication HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] Phase 1 [523396]
Company
Gilead Sciences Inc
Structure
Download
2D MOL

3D MOL

Formula
C29H37N6O9P
Canonical SMILES
CC(C)C(=O)OC1C(OC(C1(C)O)(C#N)C2=CC=C3N2N=CN=C3N)COP(=O<br />)(NC(C)C(=O)OC(C)C)OC4=CC=CC=C4
InChI
1S/C29H37N6O9P/c1-17(2)26(36)42-24-22(43-29(15-30,28(24,6)38)23-13-12-21-25(31)32-16-33-35(21)23)14-40-45(39,44-20-10-8-7-9-11-20)34-19(5)27(37)41-18(3)4/h7-13,16-19,22,24,38H,14H2,1-6H3,(H,34,39)(H2,31,32,33)/t19-,22+,24+,28+,29-,45?/m0/s1
InChIKey
YAAQYJCOIFNMKX-CVANIGNKSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Hepatitis C virus NS5B polymerase Target Info Inhibitor [532625]
References
Ref 523396ClinicalTrials.gov (NCT01316237) A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection. U.S. National Institutes of Health.
Ref 532625Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother. 2014;58(4):1930-42.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.